343 related articles for article (PubMed ID: 33149213)
1. Regulatory (FoxP3
Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
[TBL] [Abstract][Full Text] [Related]
2. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.
Dart SJ; Cook AM; Millward MJ; McDonnell AM; Chin WL; Hakeem MU; Meniawy TM; Bowyer SE
Sci Rep; 2021 Jul; 11(1):15312. PubMed ID: 34321489
[TBL] [Abstract][Full Text] [Related]
3. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
4. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
5. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Kang DH; Chung C; Sun P; Lee DH; Lee SI; Park D; Koh JS; Kim Y; Yi HS; Lee JE
Cancer Immunol Immunother; 2022 Mar; 71(3):579-588. PubMed ID: 34278517
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Tagawa T; Okamoto T; Hamatake M; Tsuchiya-Kawano Y; Otsubo K; Inoue K; Yoneshima Y; Tanaka K; Okamoto I; Nakanishi Y; Mori M
Int J Cancer; 2021 Jul; 149(2):473-482. PubMed ID: 33720422
[TBL] [Abstract][Full Text] [Related]
8. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood.
Liu T; Wang J; Liu Y; Wu J; Yuan Y; Wang C; Fang X; Li H
Technol Cancer Res Treat; 2021; 20():1533033821997817. PubMed ID: 33612078
[TBL] [Abstract][Full Text] [Related]
10. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
11. Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy.
MaruYama T; Kobayashi S; Shibata H; Chen W; Owada Y
Cancer Sci; 2021 Dec; 112(12):4844-4852. PubMed ID: 34529884
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
13. Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade.
Zheng C; Xiao Y; Chen C; Zhu J; Yang R; Yan J; Huang R; Xiao W; Wang Y; Huang C
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33876189
[TBL] [Abstract][Full Text] [Related]
14. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
[TBL] [Abstract][Full Text] [Related]
15. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.
Yamauchi T; Hoki T; Oba T; Jain V; Chen H; Attwood K; Battaglia S; George S; Chatta G; Puzanov I; Morrison C; Odunsi K; Segal BH; Dy GK; Ernstoff MS; Ito F
Nat Commun; 2021 Mar; 12(1):1402. PubMed ID: 33658501
[TBL] [Abstract][Full Text] [Related]
16. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
Tschernia NP; Gulley JL
BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
[TBL] [Abstract][Full Text] [Related]
17. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
Niu X; Wang W; Liang T; Li S; Yang C; Xu X; Li L; Liu S
Cancer Sci; 2022 Jan; 113(1):28-40. PubMed ID: 34727389
[TBL] [Abstract][Full Text] [Related]
18. Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.
Wessolly M; Stephan-Falkenau S; Streubel A; Wiesweg M; Borchert S; Mairinger E; Kollmeier J; Reis H; Bauer T; Schmid KW; Mairinger T; Schuler M; Mairinger FD
BMC Cancer; 2022 Jan; 22(1):46. PubMed ID: 34996407
[TBL] [Abstract][Full Text] [Related]
19. Establishing a whole blood CD4
Yamaguchi O; Atarashi K; Yoshimura K; Shiono A; Mouri A; Nishihara F; Miura Y; Hashimoto K; Miyamoto Y; Uga H; Seki N; Matsushima T; Kikukawa N; Kobayashi K; Kaira K; Kagamu H
BMC Cancer; 2022 Dec; 22(1):1325. PubMed ID: 36528575
[TBL] [Abstract][Full Text] [Related]
20. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
Youn JI; Park SM; Park S; Kim G; Lee HJ; Son J; Hong MH; Ghaderpour A; Baik B; Islam J; Choi JW; Lee EY; Kim HR; Seo SU; Paik S; Yoon HI; Jung I; Xin CF; Jin HT; Cho BC; Seong SY; Ha SJ; Kim HR
Sci Rep; 2020 Jun; 10(1):9050. PubMed ID: 32493990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
